0837 ET - Bristol Myers Squibb reports better-than-expected 1Q earnings and raises its full-year revenue guidance and is watching the tariff situation closely. The company says "revisions include the estimated impact of current tariffs on U.S. products shipped to China, but do not account for any potential pharmaceutical sector tariffs," it says.(adriano.marchese@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 08:37 ET (12:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.